Biomarker: T018-IgE Eucalyptus

Overview

T018-IgE Eucalyptus measures serum immunoglobulin E (IgE) antibodies directed against eucalyptus pollen allergens. IgE is involved in immediate hypersensitivity reactions by activating immune cells such as mast cells after allergen exposure. A detectable or elevated result indicates sensitization to the tested eucalyptus allergen, but does not by itself establish symptomatic allergy or predict reaction severity. The test can support evaluation of pollen-associated allergic rhinitis, conjunctivitis, asthma, or other suspected IgE-mediated reactions when interpreted with the patient’s exposure history and symptoms.

Clinical Use Cases

Support evaluation of suspected eucalyptus-pollen allergy.
Assess sensitization in patients with seasonal allergic rhinitis, allergic conjunctivitis, or asthma.
Help identify relevant aeroallergens when skin testing is unsuitable because of skin disease, medication use, or risk of a severe reaction.
Supplement, or sometimes provide an alternative to, eucalyptus allergen skin-prick testing.
Contribute to research evaluating patterns of sensitization to eucalyptus species and pollen.

Specimen Types

Venous blood serum.
Capillary blood-derived serum, when validated by the testing laboratory.

Measurement Methods

In-vitro quantitative allergen-specific IgE immunoassay.
Fluorescence-based enzyme immunoassay, including assays using allergen-coated solid phases.
Other validated automated immunochemical platforms.
Skin-prick or intradermal testing with eucalyptus pollen extract may assess the same sensitization clinically, but these are in-vivo methods rather than direct measurement of serum T018-IgE.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergen-specific IgE blood test.
Patients should provide a complete medication list. Antihistamines can affect skin-test results, but generally do not affect serum-specific IgE results; medications should not be stopped unless directed by a healthcare professional.
Results should be interpreted with exposure history, timing of symptoms, physical findings, and other allergy-test results.
A positive result indicates sensitization and does not necessarily mean that eucalyptus exposure causes symptoms.
The measured IgE concentration does not predict the severity of a future allergic reaction.
Reference ranges, reporting units, and positivity thresholds vary by assay and laboratory.
Total IgE concentration, age, ongoing allergic disease, and cross-sensitization to related pollens may influence interpretation.
Recent or current exposure is not required for serum testing, although clinical relevance depends on whether the patient’s symptoms correspond to eucalyptus exposure.